Logo

Castle Biosciences: Miles Harrison

Apr 02, 2020

Castle Biosciences has appointed Miles Harrison to its board of directors effective immediately, expanding the size of the board to eight members. Harrison will stand for election for a three-year term at the company's 2020 annual meeting of stockholders.

Since February 2016, Harrison as served as the North American president and general manager of independent global dermatology company Galderma Laboratories. He has also served as vice president and general manager of Galderma's consumer business unit. Prior to Galderma, Harrison spent most of his career at Novartis, and has held multiple leadership positions of increasing responsibility across the consumer, oncology and pharmaceuticals businesses, most recently as vice president and head of global advocacy.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.